Tuberculosis small capacity-building workshop


February 2021/1 day


Instructor-led web-based course

Objectives/learning outcomes

Upon completion of the remote on-line training, participants will be able to:

  • understand the definition of resistant and susceptible strains and the principles on which proportional method for drug susceptibility testing is based;
  • define key concepts related to drug susceptibility testing;
  • familiarise with the criteria for determining critical concentrations to test new compounds;
  • familiarise with the latest WHO recommendations on MDR-TB and Isoniazid resistant TB treatment;
  • understand the role of drug susceptibility testing for non-tuberculous mycobacteria (NTM) in clinical practice.

Target audience

Participants identified within the network. TB laboratory mid and senior level experts with at least three years of experience working on TB and/or in a microbiology laboratory.


This training seeks to strengthen capacity in Member States with regard to the diagnosis of tuberculosis. The program is developed under the European Reference Laboratory Network for Tuberculosis (ERLTB-Net, ECDC/GRANT/2018/001) by the consortium of partners managing the implementation of activities based on the network’s identified needs. Specifically, this course will cover advanced topics in TB laboratory diagnostics, focusing primarily on phenotypic-based drug susceptibility testing for both M. tuberculosis complex and non-tuberculous mycobacteria (NTMs). This course will provide participants with an overview of the most recent developments in this field, including the latest WHO recommendations on the critical concentrations and clinical breakpoints used for DST and the utility of using the minimum inhibitory concentration (MIC) in the clinical management of TB patients. This course will also cover the role of drug susceptibility testing in the clinical management of NTM-associated pulmonary disease.

Note: This course is not open for public enrolment. Participation is through invitation by the focal point of the respective disease programme or function areas which is guided by the framework of collaboration between ECDC and the Coordinating Competent Bodies of Member States.